Key result
Management by a vascular care team reduced LDL-C at 12 months compared to usual care.
Why the study?
Underutilization of therapies to reduce ischemic risk in peripheral artery disease persists.
RCT (n=114)
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The algorithm plus pharmacists was what made it work. One great thing about all of these drugs and LDL lowering is that it's really safe... and we know that the lower you go, the better the patients do.”
“The clinical pharmacist is able to help with lipid checks and medication titration in a timely manner and to make sure that the patient doesn't get lost and doesn't fall through the cracks.”
“We clearly can't get this done in the current framework, so we need to flip the model in a way that we still achieve our goals, but not necessarily place all the burden on a busy clinician who just hasn't been able—even knowing what to do—to work this into their patient care pathway.”
Supports vascular care team integration for PAD; extends education-only strategies with RCT evidence of superior outcomes.
BACKGROUND Underutilization of therapies to reduce ischemic risk in peripheral artery disease (PAD) persists. OBJECTIVES The purpose was to conduct an implementation trial of lipid management in vascular disease. METHODS The OPTIMIZE PAD-1 (Implementation of Vascular Care Team to Improve Medical Management of PAD Patients) trial randomized patients with peripheral artery disease with low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL to management via a vascular care team including a clinical pharmacist and an algorithm of intensive lipid management to achieve goal LDL-C in 1 step vs usual care plus provider education. Medications were obtained using commercial insurance. The primary endpoint was percent change in LDL-C at 12 months. RESULTS Of 166 enrolled patients, 74.2% did not have an LDL-C level at goal. Among 114 randomized patients (mean age 66 years, 36.0% women, and 15.8% Black), 50.9% received high-intensity statin, and 7.9% received ezetimibe at baseline. The mean 12-month LDL-C change was -49.1% (95% CI: -58.7% to -39.5%) with vascular care team management and -5.4% (95% CI: -15.3% to 4.6%) with usual care; the between-group least-squares mean difference was -43.7% (95% CI: -57.6% to -29.9%; P < 0.0001). Mean LDL-C was reduced in vascular care team patients from 100.6 mg/dL at baseline to 54.8 and 50.1 mg/dL by week 4 and month 12, respectively. At 12 months, vascular care team patients were >3 times as likely to achieve LDL-C <70 mg/dL and 8 times as likely to achieve LDL-C <55 mg/dL (P < 0.0001) than usual care. CONCLUSIONS OPTIMIZE PAD-1 showed that an interprofessional, algorithm-based program can achieve rapid LDL-C lowering in vascular patients using available insurance and therapies, and LDL-C targets can be met in most patients if enabled by optimized systems of care.
No takes yet. Share an insight, caveat, or question.
Hess et al. (2024) conducted an RCT in Peripheral artery disease (n=114). Vascular care team management vs. Usual care plus provider education was evaluated on Percent change in LDL-C at 12 months (MD -43.7%, 95% CI -57.6 to -29.9, p=< 0.0001). Management by a vascular care team reduced LDL-C at 12 months compared to usual care.
Synapse has enriched 10 related papers. Consider them for comparative context: